PFS: The endpoint we love and love to hate

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2606-

  Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HATE; HUMAN; LOVE; ONCOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR VOLUME; ADENOCARCINOMA; BIOASSAY; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADENOCARCINOMA; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 84878041186     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0869     Document Type: Editorial

References (2)

1. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
2. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;294: 865-7.